Cargando…
OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use
PURPOSE: To evaluate OC-01 [varenicline solution nasal spray (VNS)] tear production and symptom outcomes in patients with dry eye disease by age, gender, race, ethnicity, and artificial tear use status. PATIENTS AND METHODS: Adults ≥22 years of age diagnosed with dry eye disease, with Ocular Surface...
Autores principales: | Epitropoulos, Alice T, Daya, Sheraz M, Matossian, Cynthia, Kabat, Alan G, Blemker, Gretchen, Striffler, Kristen, Hendrix, Laura, Macsai, Marian, Gibson, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556276/ https://www.ncbi.nlm.nih.gov/pubmed/36249445 http://dx.doi.org/10.2147/OPTH.S383091 |
Ejemplares similares
-
OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2
por: Schallhorn, Julie M, et al.
Publicado: (2023) -
Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials
por: Nijm, Lisa M., et al.
Publicado: (2022) -
Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease
por: White, Darrell E, et al.
Publicado: (2023) -
Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
por: Sheppard, John D., et al.
Publicado: (2023) -
Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray
por: Wu, Xiaofei, et al.
Publicado: (2022)